Both in Biotechnology
Taysha Gene Therapies vs Novavax
Over the past year TSHA returned −8.3% and NVAX returned +22.4%; their daily moves had a correlation of 0.29.
TSHA −8.3% NVAX +22.4%Growth of $1, one year, split-adjusted
| Metric | TSHA | NVAX |
|---|---|---|
| Price | $4.09 | $9.68 |
| Market cap | $1.33B | $1.60B |
| Today | +2.25% | +1.57% |
| 1 month | −8.9% | −22.9% |
| 6 months | −41.1% | +19.5% |
| Year to date | −25.6% | +44.0% |
| 1 year | −17.5% | +15.2% |
| Revenue growth (YoY) | −100.0% | −76.3% |
| Gross margin | — | 74.9% |
| Net margin | — | −94.2% |
| P/E (TTM) | — | — |
| Price / sales | 243.0× | 3.9× |
| Net cash | $406.1M | $422.0M |
| Dividend yield | — | — |
| Volatility (60d) | 58.0% | 80.6% |
| Short % of float | 17.6% | 30.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).